Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material
This integration further streamlines access to the only approved dual GIP and GLP-1 receptor agonist without patients ever having to leave the Ro app, let alone leave their home, said Zach Reitano, co-founder & CEO of Ro
There is no evidence suggesting that slower titration, lower maximum doses, or modified schedules are needed for patients with benign thyroid nodules
The published data on how adults feel about needles is unambiguous: 2% of adults experience needle phobia, according to a 2022 international study of 2,098 adults published in PLOS ONE